{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:37:24Z","timestamp":1774733844514,"version":"3.50.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11916-024-01321-8","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T03:19:39Z","timestamp":1736997579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights"],"prefix":"10.1007","volume":"29","author":[{"given":"Isabella","family":"Henderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie","family":"Elsaadany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadie","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nehal P.","family":"Vadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"4","key":"1321_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1037\/pha0000084","volume":"24","author":"A Garcia-Romeu","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol. 2016;24(4):229\u201368. https:\/\/doi.org\/10.1037\/pha0000084.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"11","key":"1321_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","volume":"21","author":"FX Vollenweider","year":"2020","unstructured":"Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21(11):611\u201324.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"1321_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172(2):145\u201356. https:\/\/doi.org\/10.1007\/s00213-003-1640-6.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1321_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268\u201392. https:\/\/doi.org\/10.1007\/s00213-006-0457-5.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1321_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0378-8741(92)90044-r","volume":"36","author":"EB Russo","year":"1992","unstructured":"Russo EB. Headache treatments by native peoples of the Ecuadorian Amazon: a preliminary cross-disciplinary assessment. J Ethnopharmacol. 1992;36(3):193\u2013206. https:\/\/doi.org\/10.1016\/0378-8741(92)90044-r.","journal-title":"J Ethnopharmacol"},{"key":"1321_CR6","unstructured":"Kempner J. Psychedelic outlaws: the movement revolutionizing modern medicine. New York, New York: Hachette Books; 2024."},{"issue":"12","key":"1321_CR7","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","volume":"66","author":"RA Sewell","year":"2006","unstructured":"Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920\u20132. https:\/\/doi.org\/10.1212\/01.wnl.0000219761.05466.43.","journal-title":"Neurology"},{"issue":"5","key":"1321_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","volume":"47","author":"EA Schindler","year":"2015","unstructured":"Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. J Psychoactive Drugs. 2015;47(5):372\u201381. https:\/\/doi.org\/10.1080\/02791072.2015.1107664.","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"1321_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","volume":"14","author":"M Andersson","year":"2017","unstructured":"Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 2017;14(1):60. https:\/\/doi.org\/10.1186\/s12954-017-0186-6.","journal-title":"Harm Reduct J"},{"key":"1321_CR10","doi-asserted-by":"publisher","unstructured":"Schindler EAD. Psychedelics in the treatment of headache and chronic pain disorders. Disruptive Psychopharmacology. Cham: Springer International Publishing, 2022. 261-285. https:\/\/doi.org\/10.1007\/7854_2022_365.","DOI":"10.1007\/7854_2022_365"},{"issue":"4","key":"1321_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s11013-021-09749-y","volume":"46","author":"DR George","year":"2021","unstructured":"George DR, Hanson R, Wilkinson D, Garcia-Romeu A. Ancient roots of today\u2019s emerging renaissance in psychedelic medicine. Cult Med Psychiatry. 2021;46(4):890\u2013903. https:\/\/doi.org\/10.1007\/s11013-021-09749-y.","journal-title":"Cult Med Psychiatry"},{"issue":"2","key":"1321_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/02791072.2019.1606472","volume":"51","author":"RE Doblin","year":"2019","unstructured":"Doblin RE, Christiansen M, Jerome L, Burge B. The past and future of psychedelic science: An introduction to this issue. J Psychoactive Drugs. 2019;51(2):93\u20137. https:\/\/doi.org\/10.1080\/02791072.2019.1606472.","journal-title":"J Psychoactive Drugs"},{"key":"1321_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neuropharm.2018.02.018","volume":"142","author":"SJ Belouin","year":"2018","unstructured":"Belouin SJ, Henningfield JE. Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology. 2018;142:7\u201319. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.018.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1321_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","volume":"80","author":"JS Siegel","year":"2023","unstructured":"Siegel JS, Daily JE, Perry DA, Nicol GE. Psychedelic Drug Legislative Reform and Legalization in the US. JAMA Psychiat. 2023;80(1):77\u201383. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.4101.","journal-title":"JAMA Psychiat"},{"key":"1321_CR15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29167","author":"JS Kurtz","year":"2022","unstructured":"Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, Picton B, Harris M, Hatter M, Beyer R, Sahyouni R, Diaz-Aguilar LD, Castellano J, Schuster N, Abraham ME. The use of psychedelics in the treatment of medical conditions: An analysis of currently registered psychedelics studies in the American drug trial registry. Cureus. 2022. https:\/\/doi.org\/10.7759\/cureus.29167.","journal-title":"Cureus"},{"issue":"9","key":"1321_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia: Int J Headache. 2013;33(9):629\u2013808. https:\/\/doi.org\/10.1177\/0333102413485658.","journal-title":"Cephalalgia: Int J Headache"},{"issue":"9","key":"1321_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fphar.2018.00177","volume":"1","author":"EAD Schindler","year":"2018","unstructured":"Schindler EAD, Wallace RM, Sloshower JA, D\u2019Souza DC. Neuroendocrine associations underlying the persistent therapeutic effects of classic serotonergic psychedelics. Front Pharmacol. 2018;1(9):177. https:\/\/doi.org\/10.3389\/fphar.2018.00177.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1321_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/brain\/awab406","volume":"145","author":"MK Doss","year":"2022","unstructured":"Doss MK, Madden MB, Gaddis A, Nebel MB, Griffiths RR, Mathur BN, Barrett FS. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain. 2022;145(2):441\u201356. https:\/\/doi.org\/10.1093\/brain\/awab406.","journal-title":"Brain"},{"issue":"17","key":"1321_CR19","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","volume":"35","author":"R Burstein","year":"2015","unstructured":"Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619\u201329. https:\/\/doi.org\/10.1523\/JNEUROSCI.0373-15.2015.","journal-title":"J Neurosci"},{"issue":"Suppl 1","key":"1321_CR20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4103\/aian.AIAN_349_17","volume":"21","author":"DY Wei","year":"2018","unstructured":"Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster headache: epidemiology, pathophysiology, clinical features, and diagnosis. Ann Indian Acad Neurol. 2018;21(Suppl 1):S3\u20138. https:\/\/doi.org\/10.4103\/aian.AIAN_349_17.","journal-title":"Ann Indian Acad Neurol"},{"issue":"11","key":"1321_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25(11):1407\u201319. https:\/\/doi.org\/10.1038\/s41593-022-01177-4.","journal-title":"Nat Neurosci"},{"issue":"6","key":"1321_CR22","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, Tyacke RJ, Leech R, Malizia AL, Murphy K, Hobden P, Evans J, Feilding A, Wise RG, Nutt DJ. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138\u201343. https:\/\/doi.org\/10.1073\/pnas.1119598109.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1321_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/brain\/awn321","volume":"132","author":"J Peter","year":"2009","unstructured":"Peter J. Goadsby, The vascular theory of migraine\u2014a great story wrecked by the facts. Brain. 2009;132(1):6\u20137. https:\/\/doi.org\/10.1093\/brain\/awn321.","journal-title":"Brain"},{"key":"1321_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/00004647-199902000-00001","volume":"19","author":"A May","year":"1999","unstructured":"May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab. 1999;19:115\u201327.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"5","key":"1321_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1177\/0271678X20964344","volume":"41","author":"JS Dzator","year":"2021","unstructured":"Dzator JS, Howe PR, Wong RH. Profiling cerebrovascular function in migraine: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2021;41(5):919\u201344. https:\/\/doi.org\/10.1177\/0271678X20964344.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1321_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0972-2327.182302","volume":"19","author":"R Malhotra","year":"2016","unstructured":"Malhotra R. Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol. 2016;19:175\u201382.","journal-title":"Ann Indian Acad Neurol"},{"issue":"4","key":"1321_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0271678X17733655","volume":"39","author":"J Hoffmann","year":"2019","unstructured":"Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab. 2019;39(4):573\u201394. https:\/\/doi.org\/10.1177\/0271678X17733655.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"1321_CR28","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry (Abingdon, England). 2018;30(4):363\u201375. https:\/\/doi.org\/10.1080\/09540261.2018.1481827.","journal-title":"Int Rev Psychiatry (Abingdon, England)"},{"issue":"1\u20132","key":"1321_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0304-3959(02)00070-2","volume":"99","author":"K Okamoto","year":"2002","unstructured":"Okamoto K, Imbe H, Morikawa Y, Itoh M, Sekimoto M, Nemoto K, Senba E. 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain. 2002;99(1\u20132):133\u201343. https:\/\/doi.org\/10.1016\/s0304-3959(02)00070-2.","journal-title":"Pain"},{"issue":"4","key":"1321_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fcvm.2017.00048","volume":"20","author":"N Herr","year":"2017","unstructured":"Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells. Front Cardiovasc Med. 2017;20(4):48. https:\/\/doi.org\/10.3389\/fcvm.2017.00048.","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"1321_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.1468-2982.2007.01476.x","volume":"27","author":"E Hamel","year":"2007","unstructured":"Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia. 2007;27(11):1293\u2013300. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01476.x.","journal-title":"Cephalalgia"},{"issue":"2","key":"1321_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1468-2982.1998.1802094.x","volume":"18","author":"G D\u2019Andrea","year":"1998","unstructured":"D\u2019Andrea G, Granella F, Alecci M, Manzoni GC. Serotonin metabolism in cluster headache. Cephalalgia. 1998;18(2):94\u20136. https:\/\/doi.org\/10.1046\/j.1468-2982.1998.1802094.x.","journal-title":"Cephalalgia"},{"issue":"8","key":"1321_CR33","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/head.13344","volume":"58","author":"IF de Coo","year":"2018","unstructured":"de Coo IF, Wilbrink LA, Ie GD, Haan J, Ferrari MD. Aura in cluster headache: A cross-sectional study. Headache. 2018;58(8):1203\u201310. https:\/\/doi.org\/10.1111\/head.13344.","journal-title":"Headache"},{"issue":"1","key":"1321_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1526-4610.2011.02028.x","volume":"52","author":"TD Rozen","year":"2012","unstructured":"Rozen TD, Fishman RS. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache. 2012;52(1):99\u2013113. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02028.x.","journal-title":"Headache"},{"key":"1321_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11910-010-0099-1","volume":"10","author":"K Eikermann-Haerter","year":"2010","unstructured":"Eikermann-Haerter K, Ayata C. Cortical spreading depression and migraine. Curr Neurol Neurosci Rep. 2010;10:167\u201373. https:\/\/doi.org\/10.1007\/s11910-010-0099-1.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Pt 2","key":"1321_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/brain\/119.2.355","volume":"119","author":"MB Russell","year":"1996","unstructured":"Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain. 1996;119(Pt 2):355\u201361. https:\/\/doi.org\/10.1093\/brain\/119.2.355.","journal-title":"Brain"},{"issue":"8","key":"1321_CR37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/head.14597","volume":"63","author":"J Mehnert","year":"2023","unstructured":"Mehnert J, Fischer-Schulte L, May A. Aura phenomena do not initiate migraine attacks-Findings from neuroimaging. Headache. 2023;63(8):1040\u20134. https:\/\/doi.org\/10.1111\/head.14597.","journal-title":"Headache"},{"issue":"4","key":"1321_CR38","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1468-2982.1992.1204221.x","volume":"12","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12(4):221\u20138. https:\/\/doi.org\/10.1046\/j.1468-2982.1992.1204221.x. discussion 186.","journal-title":"Cephalalgia"},{"issue":"2","key":"1321_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ejp.1140","volume":"22","author":"L Arendt-Nielsen","year":"2018","unstructured":"Arendt-Nielsen L, Morlion B, Perrot S, Dahan A, Dickenson A, Kress HG, Wells C, Bouhassira D, Drewes AM. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain (London, England). 2018;22(2):216\u201341. https:\/\/doi.org\/10.1002\/ejp.1140.","journal-title":"Eur J Pain (London, England)"},{"issue":"Suppl 4","key":"1321_CR40","doi-asserted-by":"publisher","first-page":"S182","DOI":"10.1111\/j.1526-4610.2006.00602.x","volume":"46","author":"D Dodick","year":"2006","unstructured":"Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006;46(Suppl 4):S182\u201391. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00602.x.","journal-title":"Headache"},{"key":"1321_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.neuro.051508.135531","volume":"32","author":"M Costigan","year":"2009","unstructured":"Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1\u201332. https:\/\/doi.org\/10.1146\/annurev.neuro.051508.135531.","journal-title":"Annu Rev Neurosci"},{"issue":"6","key":"1321_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/j.pain.0000000000000891","volume":"158","author":"LA Wilbrink","year":"2017","unstructured":"Wilbrink LA, Louter MA, Teernstra OPM, van Zwet EW, Huygen FJPM, Haan J, Ferrari MD, Terwindt GM. Allodynia in cluster headache. Pain. 2017;158(6):1113\u20137. https:\/\/doi.org\/10.1097\/j.pain.0000000000000891.","journal-title":"Pain"},{"issue":"7","key":"1321_CR43","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1136\/rapm-2020-101273","volume":"45","author":"JP Castellanos","year":"2020","unstructured":"Castellanos JP, Woolley C, Bruno KA, Zeidan F, Halberstadt A, Furnish T. Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med. 2020;45(7):486\u201394. https:\/\/doi.org\/10.1136\/rapm-2020-101273.","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"1321_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48(1):104\u201312. https:\/\/doi.org\/10.1038\/s41386-022-01389-z.","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"1321_CR45","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/0271678X17740794","volume":"39","author":"CD Chong","year":"2019","unstructured":"Chong CD, Schwedt TJ, Hougaard A. Brain functional connectivity in headache disorders: A narrative review of MRI investigations. J Cereb Blood Flow Metab. 2019;39(4):650\u201369. https:\/\/doi.org\/10.1177\/0271678X17740794.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"8","key":"1321_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fnhum.2014.00204","volume":"27","author":"L Roseman","year":"2014","unstructured":"Roseman L, Leech R, Feilding A, Nutt DJ, Carhart-Harris RL. The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Front Hum Neurosci. 2014;27(8):204. https:\/\/doi.org\/10.3389\/fnhum.2014.00204.","journal-title":"Front Hum Neurosci"},{"key":"1321_CR47","doi-asserted-by":"publisher","first-page":"116980","DOI":"10.1016\/j.neuroimage.2020.116980","volume":"218","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020;218:116980. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.116980.","journal-title":"Neuroimage"},{"key":"1321_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.nicl.2018.03.005","volume":"18","author":"F M\u00fcller","year":"2018","unstructured":"M\u00fcller F, Dolder PC, Schmidt A, Liechti ME, Borgwardt S. Altered network hub connectivity after acute LSD administration. NeuroImage Clinical. 2018;18:694\u2013701. https:\/\/doi.org\/10.1016\/j.nicl.2018.03.005.","journal-title":"NeuroImage Clinical"},{"issue":"1","key":"1321_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1474-4422(17)30405-2","volume":"17","author":"J Hoffmann","year":"2018","unstructured":"Hoffmann J, May A. Diagnosis, pathophysiology, and management of cluster headache. Lancet Neurol. 2018;17(1):75\u201383. https:\/\/doi.org\/10.1016\/S1474-4422(17)30405-2.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1321_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40263-019-00696-2","volume":"34","author":"RB Brandt","year":"2020","unstructured":"Brandt RB, Doesborg PGG, Haan J, Ferrari MD, Fronczek R. Pharmacotherapy for cluster headache. CNS Drugs. 2020;34(2):171\u201384. https:\/\/doi.org\/10.1007\/s40263-019-00696-2.","journal-title":"CNS Drugs"},{"issue":"1","key":"1321_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-Del-Rio M, Reuter U, Uluduz D, Versijpt J, Zeraatkar D, Sacco S. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1.","journal-title":"J Headache Pain"},{"issue":"405","key":"1321_CR52","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.2.405.360-a","volume":"2","author":"E Woakes","year":"1868","unstructured":"Woakes E. On ergot of rye in the treatment of neuralgia. BMJ. 1868;2(405):360.","journal-title":"BMJ"},{"issue":"12","key":"1321_CR53","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14656566.2013.806487","volume":"14","author":"MB Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez MB, Rosas SL, Villal\u00f3n CM, VanDenBrink AM. Activation of 5-hydroxytryptamine1B\/1D\/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013;14(12):1599\u2013610. https:\/\/doi.org\/10.1517\/14656566.2013.806487.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"1321_CR54","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1468-2982.2008.01648.x","volume":"28","author":"PJ Koehler","year":"2008","unstructured":"Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia. 2008;28(11):1126\u201335. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01648.x.","journal-title":"Cephalalgia"},{"issue":"1","key":"1321_CR55","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurother\u202f: J Am Soc Exp NeuroTherapeutics. 2021;18(1):534\u201343. https:\/\/doi.org\/10.1007\/s13311-020-00962-y.","journal-title":"Neurother : J Am Soc Exp NeuroTherapeutics"},{"issue":"10","key":"1321_CR56","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, Lindsey H, Pittman BP, Cozzi NV, D\u2019Souza DC. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383\u201394. https:\/\/doi.org\/10.1111\/head.14420.","journal-title":"Headache"},{"issue":"460","key":"1321_CR57","doi-asserted-by":"publisher","first-page":"122993","DOI":"10.1016\/j.jns.2024.122993","volume":"15","author":"EAD Schindler","year":"2024","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhu Y, Pittman BP, Cozzi NV, D\u2019Souza DC. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;15(460):122993. https:\/\/doi.org\/10.1016\/j.jns.2024.122993.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1321_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","volume":"64","author":"MK Madsen","year":"2024","unstructured":"Madsen MK, Petersen AS, Stenbaek DS, S\u00f8rensen IM, Schi\u00f8nning H, Fjeld T, Nykjaer CH, Larsen SMU, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55\u201367. https:\/\/doi.org\/10.1111\/head.14656.","journal-title":"Headache"},{"issue":"9","key":"1321_CR59","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","volume":"30","author":"M Karst","year":"2010","unstructured":"Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia\u202f: Int J Headache. 2010;30(9):1140\u20134. https:\/\/doi.org\/10.1177\/0333102410363490.","journal-title":"Cephalalgia : Int J Headache"},{"issue":"10","key":"1321_CR60","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol (Oxford, England). 2022;36(10):1100\u201317. https:\/\/doi.org\/10.1177\/02698811221116926.","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"8","key":"1321_CR61","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, M\u00fcller F, Borgwardt S, Liechti ME. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiat. 2015;78(8):544\u201353. https:\/\/doi.org\/10.1016\/j.biopsych.2014.11.015.","journal-title":"Biol Psychiat"},{"issue":"14","key":"1321_CR62","doi-asserted-by":"publisher","first-page":"1214969","DOI":"10.3389\/fneur.2023.1214969","volume":"29","author":"BN Blond","year":"2023","unstructured":"Blond BN, Schindler EAD. Case report: Psychedelic-induced seizures captured by intracranial electrocorticography. Front Neurol. 2023;29(14):1214969. https:\/\/doi.org\/10.3389\/fneur.2023.1214969.","journal-title":"Front Neurol"},{"issue":"23","key":"1321_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mmcr.2018.12.007","volume":"22","author":"E Austin","year":"2018","unstructured":"Austin E, Myron HS, Summerbell RK, Mackenzie C. Acute renal injury cause by confirmed Psilocybe cubensis mushroom ingestion. Med Mycol Case Rep. 2018;22(23):55\u20137. https:\/\/doi.org\/10.1016\/j.mmcr.2018.12.007.","journal-title":"Med Mycol Case Rep"},{"issue":"6","key":"1321_CR64","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1321_CR65","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol (Oxford, England). 2022;36(2):151\u20138. https:\/\/doi.org\/10.1177\/02698811211073759.","journal-title":"J Psychopharmacol (Oxford, England)"},{"key":"1321_CR66","doi-asserted-by":"publisher","first-page":"102997","DOI":"10.1016\/j.drugpo.2020.102997","volume":"87","author":"L Gashi","year":"2021","unstructured":"Gashi L, Sandberg S, Pedersen W. Making \u201cbad trips\u201d good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int J Drug Policy. 2021;87:102997. https:\/\/doi.org\/10.1016\/j.drugpo.2020.102997.","journal-title":"Int J Drug Policy"},{"key":"1321_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology. 2018;142:143\u201366. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.012.","journal-title":"Neuropharmacology"},{"key":"1321_CR68","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels TI, Purdon J, Collins A, et al. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18:245. https:\/\/doi.org\/10.1186\/s12888-018-1824-6.","journal-title":"BMC Psychiatry"},{"issue":"4","key":"1321_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71(4):533\u201354.","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"1321_CR70","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3390\/ijms17111953","volume":"17","author":"D De Gregorio","year":"2016","unstructured":"De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci. 2016;17(11):1953.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1321_CR71","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357\u201364.","journal-title":"Addict Biol"},{"key":"1321_CR72","doi-asserted-by":"crossref","unstructured":"Ling S, Ceban F, Lui LM, Lee Y, Teopiz KM, Rodrigues NB, ..., McIntyre RS. Molecular mechanisms of psilocybin and implications for the treatment of depression. CNS Drugs. 2022;36(1):17\u201330.","DOI":"10.1007\/s40263-021-00877-y"},{"key":"1321_CR73","doi-asserted-by":"publisher","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","volume":"13","author":"CA MacCallum","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psych. 2022;13:1040217.","journal-title":"Front Psych"},{"issue":"1","key":"1321_CR74","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49(1):84\u201391. https:\/\/doi.org\/10.1080\/03602532.2016.1278228.","journal-title":"Drug Metab Rev"},{"issue":"4","key":"1321_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","volume":"14","author":"T Passie","year":"2008","unstructured":"Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther. 2008;14(4):295\u2013314.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"1321_CR76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00213-005-2183-9","volume":"180","author":"D Marona-Lewicka","year":"2005","unstructured":"Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology. 2005;180(3):427\u201335. https:\/\/doi.org\/10.1007\/s00213-005-2183-9.","journal-title":"Psychopharmacology"},{"key":"1321_CR77","doi-asserted-by":"crossref","unstructured":"Mason NL, Szabo A, Kuypers KPC, Mallaroni PA, de la Torre Fornell R, Reckweg JT, ..., Ramaekers JG. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299\u2013310.","DOI":"10.1016\/j.bbi.2023.09.004"},{"key":"1321_CR78","first-page":"245","volume":"11","author":"PP Bruno","year":"2007","unstructured":"Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci. 2007;11:245\u20138.","journal-title":"Eur Rev Med Pharmacol Sci."},{"issue":"5","key":"1321_CR79","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1468-2982.2001.00196.x","volume":"21","author":"RHA Kemper","year":"2001","unstructured":"Kemper RHA, Meijler WJ, Korf J, Ter Horst GJ. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia. 2001;21(5):549\u201357.","journal-title":"Cephalalgia"},{"issue":"1","key":"1321_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-021-01271-1","volume":"22","author":"O Kursun","year":"2021","unstructured":"Kursun O, Yemisci M, van den Maagdenberg AM, Karatas H. Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain. 2021;22(1):55.","journal-title":"J Headache Pain"},{"issue":"1","key":"1321_CR81","first-page":"1","volume":"23","author":"R Doblin","year":"1991","unstructured":"Doblin R. Pahnke\u2019s \u201cGood Friday experiment\u201d: A long-term follow-up and methodological critique. J Transpers Psychol. 1991;23(1):1\u201328.","journal-title":"J Transpers Psychol"},{"key":"1321_CR82","first-page":"295","volume":"8","author":"WN Pahnke","year":"1966","unstructured":"Pahnke WN. Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness. Int J Parapsychol. 1966;8:295\u2013314.","journal-title":"Int J Parapsychol."},{"issue":"3","key":"1321_CR83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1124\/pr.118.017160","volume":"71","author":"RL Carhart-Harris","year":"2019","unstructured":"Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev. 2019;71(3):316\u201344.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1321_CR84","doi-asserted-by":"publisher","first-page":"12702","DOI":"10.1038\/s41598-022-16325-w","volume":"12","author":"CT Golden","year":"2022","unstructured":"Golden CT, Chadderton P. Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents. Sci Rep. 2022;12(1):12702.","journal-title":"Sci Rep"},{"key":"1321_CR85","doi-asserted-by":"crossref","unstructured":"Ornelas IM, Cini FA, Wie\u00dfner I, Marcos E, Ara\u00fajo DB, Goto-Silva L, ..., Ribeiro S. Nootropic effects of LSD: Behavioral, molecular and computational evidence. Exp Neurol. 2022;356, 114148.","DOI":"10.1016\/j.expneurol.2022.114148"},{"key":"1321_CR86","doi-asserted-by":"publisher","first-page":"117653","DOI":"10.1016\/j.neuroimage.2020.117653","volume":"227","author":"AI Luppi","year":"2021","unstructured":"Luppi AI, Carhart-Harris RL, Roseman L, Pappas I, Menon DK, Stamatakis EA. LSD alters dynamic integration and segregation in the human brain. Neuroimage. 2021;227:117653.","journal-title":"Neuroimage"},{"issue":"6","key":"1321_CR87","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","volume":"239","author":"CH Murray","year":"2022","unstructured":"Murray CH, Tare I, Perry CM, Malina M, Lee R, de Wit H. Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults. Psychopharmacology. 2022;239(6):1735\u201347. https:\/\/doi.org\/10.1007\/s00213-021-05991-9.","journal-title":"Psychopharmacology"},{"issue":"4","key":"1321_CR88","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(10)70054-5","volume":"9","author":"RB Lipton","year":"2010","unstructured":"Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(10)70054-5.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1321_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10194-021-01281-z","volume":"22","author":"V Caponnetto","year":"2021","unstructured":"Caponnetto V, Deodato M, Robotti M, Koutsokera M, Pozzilli V, Galati C, Nocera G, De Matteis E, De Vanna G, Fellini E, Halili G, Martinelli D, Nalli G, Serratore S, Tramacere I, Martelletti P, Raggi A, European Headache Federation School of Advanced Studies (EHF-SAS). Comorbidities of primary headache disorders: a literature review with meta-analysis. J Headache Pain. 2021;22(1):71. https:\/\/doi.org\/10.1186\/s10194-021-01281-z.","journal-title":"J Headache Pain"},{"issue":"2","key":"1321_CR90","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10194-010-0187-2","volume":"11","author":"E Beghi","year":"2010","unstructured":"Beghi E, Bussone G, D\u2019Amico D, Cortelli P, Cevoli S, Manzoni GC, Torelli P, Tonini MC, Allais G, De Simone R, D\u2019Onofrio F, Genco S, Moschiano F, Beghi M, Salvi S. Headache, anxiety and depressive disorders: the HADAS study. J Headache Pain. 2010;11(2):141\u201350. https:\/\/doi.org\/10.1007\/s10194-010-0187-2.","journal-title":"J Headache Pain"},{"issue":"1","key":"1321_CR91","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/204946371000400103","volume":"4","author":"AK Woo","year":"2010","unstructured":"Woo AK. Depression and anxiety in pain. Rev Pain. 2010;4(1):8\u201312. https:\/\/doi.org\/10.1177\/204946371000400103.","journal-title":"Rev Pain"},{"issue":"3","key":"1321_CR92","doi-asserted-by":"publisher","first-page":"e208074","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ, Ashina S, Muenzel EJ, Hutchinson S, Pearlman EM, Lipton RB. Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study. Neurology. 2024;102(3):e208074. https:\/\/doi.org\/10.1212\/WNL.0000000000208074.","journal-title":"Neurology"},{"issue":"1","key":"1321_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.11138\/fneur\/2018.33.1.057","volume":"33","author":"P Rossi","year":"2018","unstructured":"Rossi P, Little P, De La Torre ER, Palmaro A. If you want to understand what it really means to live with cluster headache, imagine... fostering empathy through European patients\u2019 own stories of their experiences. Funct Neurol. 2018;33(1):57\u20139. https:\/\/doi.org\/10.11138\/fneur\/2018.33.1.057.","journal-title":"Funct Neurol"},{"key":"1321_CR94","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/25158163221096866","volume":"1","author":"E Freeman","year":"2022","unstructured":"Freeman E, Adair M, Beeler D, Casper R, Herman MP, Reeves D, et al. Patient-identified burden and unmet needs in patients with cluster headache: an evidence-based qualitative literature review. Cephalalgia Rep. 2022;1:5. https:\/\/doi.org\/10.1177\/25158163221096866.","journal-title":"Cephalalgia Rep."},{"issue":"2","key":"1321_CR95","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00002508-200106000-00009","volume":"17","author":"R Severeijns","year":"2001","unstructured":"Severeijns R, Vlaeyen JW, van den Hout MA, Weber WE. Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain. 2001;17(2):165\u201372. https:\/\/doi.org\/10.1097\/00002508-200106000-00009.","journal-title":"Clin J Pain"},{"issue":"1","key":"1321_CR96","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/head.14021","volume":"61","author":"MJ Burish","year":"2021","unstructured":"Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI. Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(1):117\u201324. https:\/\/doi.org\/10.1111\/head.14021.","journal-title":"Headache"},{"issue":"4","key":"1321_CR97","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ncl.2019.07.003","volume":"37","author":"A P\u00e9rez-Mu\u00f1oz","year":"2019","unstructured":"P\u00e9rez-Mu\u00f1oz A, Buse DC, Andrasik F. Behavioral Interventions for Migraine. Neurol Clin. 2019;37(4):789\u2013813. https:\/\/doi.org\/10.1016\/j.ncl.2019.07.003.","journal-title":"Neurol Clin"},{"issue":"Suppl 1","key":"1321_CR98","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10072-019-03802-w","volume":"40","author":"L Grazzi","year":"2019","unstructured":"Grazzi L, Bernstein C, Raggi A, Sansone E, Grignani E, Searl M, Rizzoli P. ACT for migraine: effect of acceptance and commitment therapy (ACT) for high-frequency episodic migraine without aura: preliminary data of a phase-II, multicentric, randomized, open-label study. Neurol Sci\u202f: Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2019;40(Suppl 1):191\u20132. https:\/\/doi.org\/10.1007\/s10072-019-03802-w.","journal-title":"Neurol Sci : Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"issue":"2","key":"1321_CR99","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jpain.2006.006","volume":"22","author":"VS Vasiliou","year":"2021","unstructured":"Vasiliou VS, Karademas EC, Christou Y, Papacostas S, Karekla M. Acceptance and commitment therapy for primary headache sufferers: a randomized controlled trial of efficacy. J Pain. 2021;22(2):143\u201360. https:\/\/doi.org\/10.1016\/j.jpain.2006.006.","journal-title":"J Pain"},{"issue":"13","key":"1321_CR100","doi-asserted-by":"publisher","first-page":"873279","DOI":"10.3389\/fpsyg.2022.873279","volume":"23","author":"DB Yaden","year":"2022","unstructured":"Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Front Psychol. 2022;23(13):873279. https:\/\/doi.org\/10.3389\/fpsyg.2022.873279.","journal-title":"Front Psychol"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-024-01321-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-024-01321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:03:03Z","timestamp":1771275783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-024-01321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1321"],"URL":"https:\/\/doi.org\/10.1007\/s11916-024-01321-8","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"14 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors. All reported studies\/experiments with human or animal subjects cited by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"None of the authors have any disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"28"}}